EcoDrugPlus

40s Ribosomal Protein S15a-Like

Ensembl ID : ENSNBRG00000020820
Gene Symbol: LOC102778020
3 Cross references
174 Possible Orthologues:

40s Ribosomal Protein S16-Like

Ensembl ID : ENSNBRG00000010637
Gene Symbol: LOC102799355
3 Cross references
313 Possible Orthologues:

40s Ribosomal Protein S19-Like

Ensembl ID : ENSNBRG00000008553
Gene Symbol: LOC102796463
3 Cross references
308 Possible Orthologues:

40s Ribosomal Protein S2-Like

Ensembl ID : ENSNBRG00000003108
Gene Symbol: LOC102800165
3 Cross references
512 Possible Orthologues:

40s Ribosomal Protein S21-Like

Ensembl ID : ENSNBRG00000008784
Gene Symbol: LOC102792338
3 Cross references
282 Possible Orthologues:

40s Ribosomal Protein S23-Like

Ensembl ID : ENSNBRG00000015717
Gene Symbol: LOC102797790
3 Cross references
382 Possible Orthologues:

40s Ribosomal Protein S24-Like

Ensembl ID : ENSNBRG00000018688
Gene Symbol: LOC102780737
3 Cross references
490 Possible Orthologues:

40s Ribosomal Protein S25-Like

Ensembl ID : ENSNBRG00000001154
Gene Symbol: LOC102789427
3 Cross references
450 Possible Orthologues:

40s Ribosomal Protein S26-Like

Ensembl ID : ENSNBRG00000017072
Gene Symbol: LOC102792443
3 Cross references
405 Possible Orthologues:

40s Ribosomal Protein S28-Like

Ensembl ID : ENSNBRG00000001485
Gene Symbol: LOC102796736
3 Cross references
276 Possible Orthologues:

40s Ribosomal Protein S3a-Like

Ensembl ID : ENSNBRG00000005834
Gene Symbol: LOC102792096
4 Cross references
360 Possible Orthologues:

40s Ribosomal Protein S4-Like

Ensembl ID : ENSNBRG00000011820
Gene Symbol: LOC102788300
3 Cross references
495 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).